ClinicalTrials.gg
CompletedNCT03282019FLOCOPUpdated Nov 20, 2024

Study of Long-term HFNC for COPD Patients with HOT

An interventional study of High-flow nasal cannula therapy and Home oxygen therapy (HOT) in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan. Completed at 1 site in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 108 studies in Pulmonary Disease, Chronic Obstructive with a site in Japan — 13 open to participants now, 16 under way, 8 of them phase 3. Pulmonary Disease, Chronic Obstructive · Japan.

Enrollment
71st of 88
120 · median 619
Started
2017
with 2 others
No phase
6 of 108
1 open now
Registered
73rd of 108
by date

Among the 108 studies in Pulmonary Disease, Chronic Obstructive with a site in Japan, this one is the 71st largest by enrollment of the 88 interventional ones that give a count, is one of 3 that started in 2017, is one of 6 with no phase, and was the 73rd registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

13 of the 108 studies in Pulmonary Disease, Chronic Obstructive with a site in Japan are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Pulmonary Disease, Chronic Obstructive with a site in Japan, or all of them as a file.
02

Study summary

This is a prospective, randomized parallel study for evaluation of the efficacy and safety of long-term nocturnal high-flow nasal cannula therapy (HFNC: with the myAIRVO2 as HFNC in this study) in stable COPD patients with the global initiative for chronic obstructive lung disease (GOLD) stage 2-4, PaCO2 >= 45 Torr and hypercapnia who require home oxygen therapy (HOT) using COPD exacerbation (Moderate or Severe).

Read the detailed description

An abroad study of the stable COPD patients was reported that HFNC usage decreased the frequency of COPD exacerbation.

In addition, the result of the pilot study (NCT02545855) of the stable COPD patient in Japan is indicated that HOT with HFNC improved their QOL and PaCO2 by comparing to HOT only.

Therefore, this study is planned to indicate the efficacy of HFNC which can increase the ventilation efficiency and have the function of heated humidification, by comparing HOT with HFNC to HOT only.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • myAIRVO2
  • high-flow nasal cannula therapy
  • home oxygen therapy
  • HOT
  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are diagnosed with the global initiative on obstructive lung disease (GOLD) stage 2-4 .
  2. Patients who have received nocturnal HOT 16 hours or more per day for 1 month or more at the time of the .
  3. Patients with PaCO2 >= 45 Torr and pH >= 7.35 at screening.
  4. Patients with COPD exacerbation (Moderate or Severe; judged by the investigators) within the past 1 year prior to the informed consent.
  5. Patients who are more than 40 years old at the time of the informed consent.
  6. Patients who agree to participate in the study with the written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe kidney, liver or cardiovascular disease.
  2. Patients with active malignant tumor.
  3. Patients with acute disease.
  4. Patients who are diagnosed with asthma. (Excluding patients with history of asthma).
  5. Patients who have any history of obstructive sleep apnea syndrome (OSAS) or are highly-suspected cases in the clinical. (Excluding patients who are denied the diagnosis of OSAS by the result of overnight polysomnography.)
  6. Patients with diseases that affecting the efficacy endpoints (for example: active pulmonary infection, pulmonary fibrosis and bronchiectasis, α-1-antitrypsin deficiency etc.,) and are regarded as inadequate for the study by the investigators.
  7. Patients who have experienced a COPD exacerbation (any Severity: judged by the investigators) within the past 4 weeks prior to the .
  8. Patients who are receiving nocturnal noninvasive positive pressure ventilation (NPPV), or who had been received it within 4 weeks prior to the informed consent.
  9. Patients who have used HFNC at home within the past 1 year prior to the informed consent, or are using any HFNC. (Excluding patients who used HFNC during hospitalization due to acute respiratory failure within 1 year prior to the informed consent.)
  10. Patients with history of tracheotomy, severe pharyngeal surgery or severe nasal cavity surgery within the past 6 months prior to the informed consent.
  11. Patients who are pregnant.
  12. Patients with cognitive impairment or mental disorder who are regarded as inadequate to evaluate for the study by the investigators.
  13. Patients who are regarded as being unable to operate the myAIRVO2 adequately at home by the investigators.
  14. Patients who have participated in the other study at the time of the informed consent, or will participate in the other study.
  15. Any other cases who are regarded as inadequate for the study enrollment by the investigators.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Arm A(myAIRVO2® + HOT)

    Subjects receive following protocol treatment; Home oxygen therapy (HOT) plus nocturnal high-flow nasal cannula therapy with the myAIRVO2 within 52weeks.

    Device: High-flow nasal cannula therapy · Device: Home oxygen therapy (HOT)

  • Active comparator
    Arm B(HOT)

    Subjects receive following protocol treatment; Home oxygen therapy (HOT) only within 52weeks.

    Device: Home oxygen therapy (HOT)

Interventions

  • DeviceHigh-flow nasal cannula therapy

    Subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current Home oxygen therapy (HOT). The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.

    Also known as: myAIRVO2®

  • DeviceHome oxygen therapy (HOT)

    All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.

06

What researchers measure

Primary outcomes

  1. Frequency (the number of occurrences per year) of COPD exacerbation (Moderate or Severe)

    COPD exacerbation will be assessed by the disease diary which is kept by each patient within the term of intervention.

    Time frame: 52weeks

Secondary outcomes

  1. Term from enrollment to the date of first COPD exacerbation (Moderate or Severe)

    The term from enrollment to the date of first COPD exacerbation is a duration from the start of intervention (Week0) to the date of first COPD exacerbation or death from any cause which ever comes first. The date of first COPD exacerbation will be assessed by the disease diary which is kept by each patient within the term of intervention.

    Time frame: up to 52 weeks

  2. Term from enrollment to death from any cause

    Term from enrollment to death from any cause is a duration from the start of intervention (Week0) to death from any cause.

    Time frame: up to 52 weeks

  3. Frequency (the number of occurrences per year) of COPD exacerbation (All Severity and Severe only)

    COPD exacerbation will be assessed by the disease diary which is kept by each patient within the term of intervention.

    Time frame: 52weeks

  4. Total St. George's respiratory questionnaire (SGRQ-C) score, and each components score (symptom score, activity score, and impact score)

    SGRQ-C score will be assessed by Japanese version of the SGRQ-C value sets including each components score (symptom score, activity score, and impact score).

    Time frame: at 0, 12, 24 and 52 weeks

  5. Quality-adjusted life year (QALY) by mapping the EQ-5D-5L utility scores

    Quality-adjusted life year (QALY) of the subjects will be assessed by Japanese version of the EQ-5D-5L value sets including assessment of changes from baseline in the EQ-5D-5L utility index scores and visual analogue scale scores.

    Time frame: at 0, 12, 24 and 52 weeks

  6. Total SRI (Severe Respiratory Insufficiency Questionnaire) score

    Total SRI score will be assessed by Japanese version of the SRI value sets.

    Time frame: at 0, 12, 24 and 52 weeks

  7. Total PSQI-J(Japanese version of the Pittsburgh Sleep Quality Index) score

    Total PSQI-J score will be assessed by Japanese version of the PSQI value sets.

    Time frame: at 0, 12, 24 and 52 weeks

  8. Dyspnea intensity: the modified medical research council (mMRC) score

    Dyspnea intensity will be evaluated by the modified medical research council (mMRC) score.

    Time frame: 52weeks

  9. Arterial blood gas analysis (ABG): pH, PaO2, PaCO2, HCO3-, BE

    ABG will be evaluated by the blood gas analysis equipment.

    Time frame: 52weeks

  10. Oxygen Saturation (SpO2)

    SpO2 will be evaluated by Pulse Oximeter.

    Time frame: 52weeks

  11. Pulmonary functions: FVC, FEV1, FEV1%

    Lung function of the subjects will be assessed by the pulmonary function tests in the following indicators: vital capacity (VC, %VC), forced vital capacity (FVC, %FVC), forced expiratory volume in 1 second (FEV1, %FEV1), FEV1/FVC.

    Time frame: 52weeks

  12. 6-minute walk test (6MWT)

    6MWT for the respiration rehabilitation is defined as the functional exercise capacity which is assessed by the following indicators: the distance (m), changes in pre- and post-6MWT pulse oximeter (SpO2), and post-6MWT modified borg scale.

    Time frame: at 0, 12, 24 and 52 weeks

  13. Term from enrollment to the date of long-term (more than 1month) NPPV(Noninvasive Positive Pressure Ventilation) usage

    The term from the start of intervention (Week0) to the date of Long-term NPPV usage. Long-term NPPV usage is defined as more than 1month NPPV usage.

    Time frame: 52weeks

  14. Flow rate(Oxygen / Total) (Arm A only)

    Oxygen flow rate / Total flow rate will be confirmed by the record of numerical value displayed on the device.

    Time frame: 52weeks

  15. Total hours of myAIRVO2-use (Arm A only)

    Total hours of myAIRVO2-use will be confirmed by the record of numerical value displayed on the device.

    Time frame: 52weeks

  16. Adverse events

    Adverse events will be determined by the latest version of MedDRA/J (Medical Dictionary for Regulatory Activities/J)at the time of Database lock.

    Time frame: 52weeks

Other outcomes

  1. Correlation between frequency of COPD exacerbation (All Severity and Severe only) and amount of ABG change

    Amount of ABG change will be calculated by the ABG value at before and after the intervention.

    Time frame: 52weeks

  2. Correlation between frequency of COPD exacerbation (All Severity and Severe only) and amount of SpO2 change

    Amount of SpO2 change will be calculated by the ABG value of before and after the intervention.

    Time frame: 52weeks

07

Study locations

1 site
  • Kobe City Medical Center General Hospital
    Kobe, Hyogo 6500047, Japan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Oct 2020, 37 months.

Of 1,097 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 37 months is above that.

Counting every sponsor, half of 1,185 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2017
First posted
Sep 13, 2017
StartActual
Sep 6, 2017
Primary completionActual
Oct 28, 2020
CompletionActual
Oct 28, 2020
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03282019
Lead sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Collaborators
Kobe City Medical Center General Hospital
Responsible party
Sponsor
First posted
Sep 13, 2017
Start date
Sep 6, 2017
Primary completion
Oct 28, 2020
Completion
Oct 28, 2020
Last update
Nov 20, 2024

Study contacts

Keisuke Tomii, MD, Ph.D.
principal investigator · Kobe City Medical Center General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion